EUVIMEDEUVIMED entdecken
Crossref

Platelet based regimen in desensitization of highly sensitized patients with kidney transplantation. A novel therapy

Sara Hasibi, Eghlim Nemati, Mohammad Javanbakht, Behzad Einollahi

Transplant Immunology · 2026

DOI: 10.1016/j.trim.2026.102433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2026. Verfasst von Sara Hasibi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Urology Research Center, Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Kidney Transplantation, Desensitization, Immunologic, Graft Rejection, Blood Platelets. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Kidney transplantation remains the best treatment for patients with renal failure. Some patients, however, have high levels of anti-human leukocyte antigen (anti-HLA) antibodies so transplantation is not possible for them. To address this, we used desensitization, where plasmapheresis and intravenous immunoglobulin replaced with a new platelet-based approach to lower costs and reduce complications. We then assessed graft survival after transplantation. METHODS: In this historical cohort study, we enrolled 48 patients with calculated panel of reactive antibodies (cPRA) levels greater than 90% who were eligible for desensitization between 2018 and 2024. All patients received a desensitization regimen consisting of bortezomib, rituximab, and platelets, followed by kidney transplantation. Post-transplant, all patients were monitored for graft and patient survival. RESULTS: Among the 48 transplanted patients, only three (6.3%) experienced acute rejection during the six-year follow-up period. The six-year censored graft and patient survival were 98% and 97% calculated using the life-table method. Patient survival for one and six years was 97% and 68%, respectively. CONCLUSION: The study demonstrated that a desensitization regimen combining rituximab, bortezomib and platelets effectively reduced cPRA in highly sensitized patients, thereby enhancing their eligibility for transplantation. Additionally, this approach is associated with a significant reduction in rejection rates compared to conventional desensitization regimens, highlighting its advantages in improving transplant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationDesensitization, ImmunologicGraft RejectionBlood PlateletsHumansFemaleMaleMiddle AgedAdultGraft SurvivalRituximabBortezomibHLA AntigensIsoantibodiesPlasmapheresisImmunoglobulins, IntravenousFollow-Up Studies

Stichwörter der Autor:innen

DesensitizationPlateletsSurvivalTransplantation

Substanzen

RituximabBortezomibHLA AntigensIsoantibodiesImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Nephrology and Urology Research Center, Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Nephrology and Urology Research Center, Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: behzadeinollahi@finmail.com.

Zitieren

APA

Hasibi, S., Nemati, E., Javanbakht, M., & Einollahi, B. (2026). Platelet based regimen in desensitization of highly sensitized patients with kidney transplantation. A novel therapy. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102433

Vancouver

Hasibi S, Nemati E, Javanbakht M, Einollahi B. Platelet based regimen in desensitization of highly sensitized patients with kidney transplantation. A novel therapy. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102433

BibTeX
@article{Hasibi2026,
  author = {Hasibi, Sara and Nemati, Eghlim and Javanbakht, Mohammad and Einollahi, Behzad},
  title = {Platelet based regimen in desensitization of highly sensitized patients with kidney transplantation. A novel therapy},
  journal = {Transplant Immunology},
  year = {2026},
  doi = {10.1016/j.trim.2026.102433}
}
Kostenlos starten →